All In Biotech

Drug Trial Radar · NCT04856917

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

123

Actual

Start

May 15, 2021

Primary completion

Feb 1, 2022

Study completion Mar 29, 2022

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris

Conditions

  • Acne Vulgaris

Interventions

  • ImsidolimabDrug

    Humanized Monoclonal Antibody

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Facial Inflammatory Lesion Counts at Week 12Time frame: Baseline, Week 12

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Site 10-114

    Hot Springs, Arkansas

  • Site 10-111

    Fountain Valley, California

  • Site 10-106

    Sherman Oaks, California

  • Site 10-113

    Sweetwater, Florida

  • Site 10-108

    Tampa, Florida

  • Site 10-107

    Tampa, Florida

  • Site 10-109

    New Orleans, Louisiana

  • Site 10-112

    New Orleans, Louisiana

  • Site 10-104

    Detroit, Michigan

  • Site 10-110

    Portsmouth, New Hampshire

  • Site 10-105

    Murfreesboro, Tennessee

  • Site 10-103

    Austin, Texas

  • Site 10-102

    College Station, Texas

  • Site 10-101

    San Antonio, Texas

  • Site 10-115

    Waterloo, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.